MedTrace Logo

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

NCT06497699 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2025-09-03

Study results available
· View outcomes & findings →

Summary

This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.

Conditions

Interventions

DRUG

Dexycu

single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone

Sponsors & Collaborators

  • Ocumension Therapeutics (Shanghai) Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Zhixun Li · Ocumension Therapeutics (Shanghai) Co., Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2023-07-08
Completion
2023-12-14
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06497699 on ClinicalTrials.gov